Thursday, February 3, 2011

Gemzar/gemcitabine should help Venus profit soar by 40% to 100% from current levels

Annualised WW Branded sales of Gemzar is $1.5 billion. The cumulative sales of Gemzar for the target market ( Poland, Slovenia, Germany, Portugal) put together is around 10% of global sales. With this approval in UK and several others expected geographies ( 2q-2011), the opportunity can fetch about $10m to 20m in annual sales for Venus remedies. Gemzar branded sales in Germany, UK, Slovenia Portugal and UK put together is $150m. Cytotoxic injectables being a high value business, the net profit margin would for be in the range of 50%.